Prediction: This Stock Will Beat the Market in 2025

It hasn't been a great year for Iovance Biotherapeutics (NASDAQ: IOVA), an innovative mid-cap biotech company. The drugmaker's shares have significantly lagged the market -- advancing only about 5% so far this year. Iovance faces several issues, but it has plenty of opportunities, too.In fact, several catalysts could lead the company to perform much better in 2025 than it did this year -- and perhaps even better than the broader equity market. Let's look deeper into how Iovance Biotherapeutics could pull that off.In February, Iovance earned approval from the U.S. Food and Drug Administration (FDA) for Amtagvi, a medicine for advanced melanoma (the most severe form of skin cancer). Amtagvi is a tumor-infiltrating lymphocyte (TIL) therapy. It is manufactured using patients' own TIL cells, which can identify and kill cancer cells. The manufacturing process for Amtagvi takes 34 days. Due to the complexity of this type of therapy, it is manufactured in qualified authorized treatment centers (ATCs).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool